Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma

Oncology

Volumn 82, Issue 1, 2012, Pages 59-66

  Shao, Yu Yun ^a,b   Lin, Zhong Zhe ^a,b   Hsu, Chiun ^a,b   Lee, Kuan Der ^c   Hsiao, Chi Huang ^d   Lu, Yen Shen ^a   Huang, Chien Chung ^a   Shen, Yin Chun ^a   Hsu, Chih Hung ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Interleukin 6; Interleukin 8; Metronomic chemotherapy; Thalidomide

Indexed keywords

ANGIOGENIC FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; PHARMACOLOGICAL BIOMARKER; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UFT; UFUR; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEPATITIS B; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; LEUKOPENIA; LIVER CELL CARCINOMA; MALAISE; MALE; METRONOMIC DRUG ADMINISTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PRURITUS; RASH; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS B VIRUS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; THALIDOMIDE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862824694     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000336126     Document Type: Article

References (34)

1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
3. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL: Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65: 242-249. (Pubitemid 37505832)
4. Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK: Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10: 649-653. (Pubitemid 38351529)
5. Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, Abbruzzese JL, Brown TD: Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial. Cancer 2005; 103: 749-755. (Pubitemid 40216403)
6. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L: Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103: 119-125. (Pubitemid 39665464)
7. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-978. (Pubitemid 27314772)
8. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-466. (Pubitemid 28269042)
9. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-436. (Pubitemid 38745528)
10. Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 6938-6943. (Pubitemid 35424084)
11. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-R24. (Pubitemid 30217701)
12. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010; 53: 126-131.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300. (Pubitemid 46630787)
15. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
16. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-1721. (Pubitemid 38501140)
17. Tang TC, Man S, Lee CR, Xu P, Kerbel RS: Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia 2010; 12: 264-274.
18. Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS: Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 2010; 12: 928-940.
19. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC: Prognosis of advanced hepatocellular carcinoma: Comparison of three staging systems in two French clinical trials. Ann Oncol 2008; 19: 1117-1126. (Pubitemid 351796337)
20. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK: Advanced hepatocellular carcinoma: Which staging systems best predict prognosis? J Clin Oncol 2010; 28: 2889-2895.
21. Shao YY, Hsu CH, Lin ZZ, Hsu C, Cheng AL: Predicting prognosis of patients with advanced hepatocellular carcinoma treated with antiangiogenic therapy using the CUPI and CLIP staging systems (abstract). J Clin Oncol 2011; 29(suppl):e14669.
22. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL: Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 102: 981-986.
23. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL: Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-4596.
24. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850.
25. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009; 27: 3027-3035.
26. Waugh DJ, Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
27. Gabay C: Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8(suppl 2): S3.
28. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ: Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 2011; 128: 2038-2049.
29. Santer FR, Malinowska K, Culig Z, Cavarretta IT: Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 2010; 17: 241-253.
30. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ: Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 2008; 29: 1148-1156. (Pubitemid 351958693)
31. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K, Aikou T: Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol 2005; 12: 800-807. (Pubitemid 41355932)
32. Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K: Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26: 1604-1611.
33. Shao YY, Hsu CH, Huang CC, Cheng AL: Use of plasma angiogenesis-related factors to investigate the association of interleukin 8 and interleukin 6 levels with efficacy of sorafenib-based antiangiogenic therapy in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011; 29:abstr 199 (suppl 194
34. Greene FL, Page DL, Flemming ID, et al: AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002.